Advertisement

Ads Placeholder
Loading...

SynBiotic SE

SBX.DEXETRA
Healthcare
Drug Manufacturers - Specialty & Generic
1.90
-0.13(-6.17%)
German Market opens in 1h 3m

SynBiotic SE Fundamental Analysis

SynBiotic SE (SBX.DE) shows weak financial fundamentals with a PE ratio of -0.85, profit margin of -2.75%, and ROE of -55.39%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position31.01%
PEG Ratio-0.01

Areas of Concern

ROE-55.39%
Operating Margin-2.90%
Current Ratio0.81
We analyze SBX.DE's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -301.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-301.3/100

We analyze SBX.DE's fundamental strength across five key dimensions:

Efficiency Score

Weak

SBX.DE struggles to generate sufficient returns from assets.

ROA > 10%
-30.44%

Valuation Score

Excellent

SBX.DE trades at attractive valuation levels.

PE < 25
-0.85
PEG Ratio < 2
-0.01

Growth Score

Weak

SBX.DE faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

SBX.DE shows balanced financial health with some risks.

Debt/Equity < 1
0.23
Current Ratio > 1
0.81

Profitability Score

Weak

SBX.DE struggles to sustain strong margins.

ROE > 15%
-5539.23%
Net Margin ≥ 15%
-2.75%
Positive Free Cash Flow
No

Key Financial Metrics

Is SBX.DE Expensive or Cheap?

P/E Ratio

SBX.DE trades at -0.85 times earnings. This suggests potential undervaluation.

-0.85

PEG Ratio

When adjusting for growth, SBX.DE's PEG of -0.01 indicates potential undervaluation.

-0.01

Price to Book

The market values SynBiotic SE at 0.57 times its book value. This may indicate undervaluation.

0.57

EV/EBITDA

Enterprise value stands at -0.51 times EBITDA. This is generally considered low.

-0.51

How Well Does SBX.DE Make Money?

Net Profit Margin

For every $100 in sales, SynBiotic SE keeps $-2.75 as profit after all expenses.

-2.75%

Operating Margin

Core operations generate -2.90 in profit for every $100 in revenue, before interest and taxes.

-2.90%

ROE

Management delivers $-55.39 in profit for every $100 of shareholder equity.

-55.39%

ROA

SynBiotic SE generates $-30.44 in profit for every $100 in assets, demonstrating efficient asset deployment.

-30.44%

Following the Money - Real Cash Generation

Operating Cash Flow

SynBiotic SE generates limited operating cash flow of $-2.93M, signaling weaker underlying cash strength.

$-2.93M

Free Cash Flow

SynBiotic SE generates weak or negative free cash flow of $-2.95M, restricting financial flexibility.

$-2.95M

FCF Per Share

Each share generates $-0.62 in free cash annually.

$-0.62

FCF Yield

SBX.DE converts -32.62% of its market value into free cash.

-32.62%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.85

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.01

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.57

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.34

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.23

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.81

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.55

vs 25 benchmark

ROA

Return on assets percentage

-0.30

vs 25 benchmark

ROCE

Return on capital employed

-0.42

vs 25 benchmark

How SBX.DE Stacks Against Its Sector Peers

MetricSBX.DE ValueSector AveragePerformance
P/E Ratio-0.8528.54 Better (Cheaper)
ROE-55.39%738.00% Weak
Net Margin-275.31%-43982.00% (disorted) Weak
Debt/Equity0.230.34 Strong (Low Leverage)
Current Ratio0.812806.01 Weak Liquidity
ROA-30.44%-14624.00% (disorted) Weak

SBX.DE outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews SynBiotic SE's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ